Leflunomid Bluefish

Leflunomide, the active ingredient in Leflunomid Bluefish, is a disease-modifying antirheumatic drug (DMARD) presented as an oral tablet for oral use. It treats rheumatoid arthritis and psoriatic arthritis in adult patients.

GNH USA supplies Leflunomid Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a DMARD that modulates immune activity in inflammatory joint diseases.

- Rheumatoid arthritis: reduces disease activity, slows joint damage, and improves functional status. - Psoriatic arthritis: alleviates joint inflammation and skin lesions, helping achieve disease control. - Inadequate response to conventional DMARDs: provides an alternative therapeutic option for adults with persistent disease activity.

Leflunomid Bluefish may cause a range of adverse reactions. Patients should be monitored regularly for both common and serious events.

Common Side Effects: - Diarrhoea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Alopecia: reversible hair thinning. - Elevated liver enzymes: mild transaminase rise. - Hypertension: increase in blood pressure readings. - Rash: non‑specific skin eruption.

Serious or Rare Side Effects: - Severe liver injury: jaundice, hepatic failure. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions. - Bone marrow suppression: pancytopenia, neutropenia. - Interstitial lung disease: cough, dyspnoea, pulmonary infiltrates. - Serious infections: opportunistic bacterial or viral infections. - Teratogenicity: fetal malformations when exposure occurs in pregnancy.

Leflunomid Bluefish requires careful monitoring and specific safety measures.

- Pregnancy contraindication: avoid use in women who are pregnant or may become pregnant; teratogenic risk is high. - Liver function monitoring: obtain baseline tests and repeat regularly during therapy. - Hematologic monitoring: perform complete blood counts to detect bone‑marrow suppression. - Renal impairment: adjust use in patients with severe renal dysfunction. - Active infection: defer initiation until infection resolves. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Leflunomid Bluefish can interact with several medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Cholestyramine or colestipol: reduces leflunomide absorption, lowering therapeutic levels. - Live vaccines: heightened risk of infection due to immunosuppression. - Hepatotoxic drugs (e.g., azathioprine, methotrexate): additive liver injury. - Strong CYP1A2 inhibitors: may raise teriflunomide concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate hypertension and renal effects. - ACE inhibitors or ARBs: potential for increased blood pressure. - Statins: possible additive liver enzyme elevation. - Oral contraceptives: reduced efficacy, consider alternative contraception. - Immunosuppressants (e.g., cyclosporine): monitor for enhanced immunosuppression.